Karnataka Mail

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Spasticity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.

Some of the key takeaways from the Spasticity Pipeline Report:

• Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years. 
• Spasticity companies working in the treatment market are Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharmaceuticals, RVL Pharmaceuticals, MedtronicNeurp, Medy-Tox, Sun Pharma, GlaxoSmithKline, Canbex Therapeutics Ltd, and others, are developing therapies for the Spasticity treatment 

• Emerging Spasticity therapies in the different phases of clinical trials are- Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, arbaclofen, intrathecal baclofen, Meditoxin, SPARC110, Botulinum toxin A (GSK1358820), VSN16R, and others are expected to have a significant impact on the Spasticity market in the coming years.   
• Nabiximols, a cannabis oral spray, was used to treat patients in two MS clinical studies for spasticity, which is characterised by increased muscle stiffness and spasms typical of people with multiple sclerosis (MS). The company that created nabiximols, GW Pharmaceuticals, which is now a division of Jazz Pharmaceuticals, supported the research
• The first participant in the Phase II RAISE Spasticity trial of SL-1002 for people with limb spasticity has received a dosage from Saol Therapeutics. The business anticipated topline trial results early the following year
• In July 2021, Huons initiated a multi center, Phase III clinical trial to evaluate the safety and efficacy ofHU-014 Inj in the Treatment of Post Stroke Upper Limb Spasticity. HU-014 Inj was given an injection to 5 Upper limbmuscle (Total 360U/, IM). Currently the trial is active and recruiting and anticipated to be completed by November 2022with 198 participants
• In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market and commercializea botulinum toxin in the United States and Canada. Aquavit has been investing in its proprietary delivery technologies andrelated intellectual property for botulinum toxin and recently proved its efficacy and safety through a clinical study.

Spasticity Overview

Spasticity is a disorder marked by an unnatural rise in muscular tone or stiffness, which may impair speech or movement and be accompanied by discomfort or pain. Damage to the nerve pathways in the brain or spinal cord that regulate muscle action is the usual cause of spasticity.

Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spasticity-pipeline-insight

Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:

• Lu AG06466: Lundbeck
• DAXXIFY: Revance Therapeutics
• IPN10200: Ipsen
• SIL 1002: Saol Therapeutics
• HU-014: Huons
• MYOBLOC: Supernus Pharmaceuticals
• arbaclofen: RVL Pharmaceuticals
• intrathecal baclofen: MedtronicNeurp
• Meditoxin: Medy-Tox
• SPARC1103: Sun Pharma
• Botulinum toxin A (GSK1358820): GlaxoSmithKline
• VSN16R: Canbex Therapeutics Ltd

Route of Administration

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Spasticity Pipeline Therapeutics Assessment

• Spasticity Assessment by Product Type
• Spasticity By Stage and Product Type
• Spasticity Assessment by Route of Administration
• Spasticity By Stage and Route of Administration
• Spasticity Assessment by Molecule Type
• Spasticity by Stage and Molecule Type

DelveInsight’s Spasticity Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies

Some of the key companies in the Spasticity Therapeutics Market include:

Key companies developing therapies for Spasticity are – Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc., and others.

Spasticity Pipeline Analysis:

The Spasticity pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
• Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spasticity drugs and therapies

Spasticity Pipeline Market Drivers

• Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market, increasing R&D for developing effective therapies are some of the important factors that are fueling the Spasticity Market.

Spasticity Pipeline Market Barriers

• However, high cost of the treatment, lack of disease awareness in emerging economies and other factors are creating obstacles in the Spasticity Market growth.

Scope of Spasticity Pipeline Drug Insight    

• Coverage: Global
• Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharmaceuticals, RVL Pharmaceuticals, MedtronicNeurp, Medy-Tox, Sun Pharma, GlaxoSmithKline, Canbex Therapeutics Ltd, and others
• Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, arbaclofen, intrathecal baclofen, Meditoxin, SPARC110, Botulinum toxin A (GSK1358820), VSN16R, and others
• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies
• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers 

Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services